Track topics on Twitter Track topics that are important to you
Roivant Sciences and Poxel have signed a strategic development and license agreement for imeglimin, an investigational oral therapy which has been developed by Poxel for the potential treatment of typ...
Roivant Sciences and Poxel will develop globally Poxel's imeglimin in all but 13 Asian nations in a deal that could generate -More-
Roivant Sciences will partner with Poxel to co-develop its Phase III-ready lead candidate, the type 2 diabetes treatment imeglimin, in the U.S., Europe, and elsewhere in the world except 13 Asian nati...
Poxel SA licensed Roivant Sciences GMBH rights to develop and commercialize its Type II diabetes compound imeglimin in the US, Europe, and all other countries except certain Asian territories where Po...
Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s experimental drug imeglimin for a range of metabolic disorders in...
NewsRoivant will be responsible for development and commercialization costs and Poxel will contribute $25 million to the development program. The parties will decide on a potential co-promotion prior ...
Poxel SAJonae R. Barnes, +1 617-818-2985Senior Vice President, Investor Relations and Public Relationsjonae.email@example.comInvestor relations / Media - EU/USTrophic Communicati...
France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative...
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of ...
Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...
We have published hundreds of POXEL S.A. news stories on BioPortfolio along with dozens of POXEL S.A. Clinical Trials and PubMed Articles about POXEL S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of POXEL S.A. Companies in our database. You can also find out about relevant POXEL S.A. Drugs and Medications on this site too.